Brainxell, Inc.

Madison, WI Brainxell, Inc.

UEI
CFGFE23M73T7
CAGE
7EV37
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
455 Science Dr #210, Madison, WI 53711, USA
Website
brainxell.com
Founded
2015
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Brainxell, Inc.'s 5 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Brainxell, INC:1270448 [24-007322] Contract · 75N95024P00619 National Institute on Drug Abuse $18,725
Accelerating functional maturation of human ipsc-derived astrocytes - project summary/abstract neurological and… Grant · R43MH135527 National Institute of Mental Health $275,615
Brainxell, INC:1270448 [21-005362] Contract · 75N95021P00461 National Institute on Drug Abuse $35,440
Generation of stable egfp-expressing ipsc line, CAT. No. BX-6021, QTY: 7; differentiation to spinal motor neurons from… Contract · 75N95021P00227 National Institute on Drug Abuse $130,500
Accelerating functional maturation of human ipsc-derived microglia - project summary/abstract neurological and… Grant · R43AG073055 National Institute on Aging $765,651

About Brainxell, Inc.

Brainxell, Inc. is a for-profit corporate entity located in Madison, Wisconsin, specializing in the manufacturing of human neuron cells and related services for neurological disease research and drug discovery. Registered in SAM.gov since July 2015, the company provides sophisticated cellular engineering solutions, focusing on developing advanced human cell lines derived from induced pluripotent stem cells (iPSCs). Their core competency involves creating specialized neural cell types, including neurons, astrocytes, and microglia, which are critical for advancing medical research and pharmaceutical development in neurological and psychiatric disorder domains.

Through federal contract awards, Brainxell, Inc. has primarily worked with agencies within the National Institutes of Health (NIH), including the National Institute on Drug Abuse, National Center for Advancing Translational Sciences, and National Institute on Alcohol Abuse and Alcoholism. The company has received multiple purchase order contracts totaling approximately $213,240, with contract values ranging from $11,900 to $130,500. These contracts involved specialized services such as generating stable EGFP-expressing iPSC lines, differentiating iPSCs into spinal motor neurons, producing CRISPR-engineered cells, and creating differentiated neurons for evaluating neuronal infectivity of SARS-CoV-2. Most contracts were awarded without specific set-aside designations, with one small business set-aside contract noted.

Brainxell, Inc. has secured two significant federal grant awards from NIH institutes, specifically the National Institute of Mental Health and the National Institute on Aging. These Phase I SBIR grants, valued at undisclosed amounts, focus on accelerating the functional maturation of human iPSC-derived brain cells. The R43MH135527 grant aims to develop methods for rapidly generating mature astrocytes, while the R43AG073055 grant concentrates on creating mature microglia. Both grants share a common objective of improving drug discovery platforms by developing more advanced, mature human brain cell models. The research targets understanding and potentially treating neurological and psychiatric disorders, including Alzheimer's disease, by creating more sophisticated cellular screening platforms that can better represent mature human brain cell characteristics.

Quick answers

What is Brainxell, Inc.'s UEI?

Brainxell, Inc.'s Unique Entity ID (UEI) in SAM.gov is CFGFE23M73T7.

What is Brainxell, Inc.'s CAGE code?

Brainxell, Inc.'s CAGE code is 7EV37.

What is Brainxell, Inc.'s primary NAICS code?

Brainxell, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Brainxell, Inc. located?

Brainxell, Inc.'s physical address in SAM.gov is 455 Science Dr #210, Madison, WI 53711, USA.

Is Brainxell, Inc. registered in SAM.gov?

Yes. Brainxell, Inc.'s SAM.gov registration is active through January 29, 2027.

What is Brainxell, Inc.'s most recent federal award?

Brainxell, Inc.'s most recent federal contract award is Brainxell, INC:1270448 [24-007322] (75N95024P00619), from National Institute on Drug Abuse, on September 16, 2024.

On GovTribe

See Brainxell, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors